Jade Biosciences, Inc. Retained Earnings
Jade Biosciences, Inc. (JBIO) had Retained Earnings of -$270.52 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$270.52M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$214.76M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$174.39M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$142.46M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$270.52M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | -$214.76M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$174.39M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | -$142.46M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$117.28M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$235.57M 10-Q · filed 2025-04-25 | |
| 2024-12-31 | -$46.98M 10-K · filed 2026-03-06 | -$233.05M 10-K · filed 2025-03-27 |
| 2024-09-30 | -$227.62M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$211.38M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$186.61M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$163.42M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$143.01M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$123.45M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$104.42M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$87.90M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$72.88M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$59.29M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$47.30M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$36.39M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$28.17M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$21.98M 10-Q · filed 2021-08-16 | |
| 2020-12-31 | -$13.41M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |